Wealthcreatures.com
KOPRAN FRESH BRRAKOUT AVOVE 126.50 READY FOR NEW ALL TIME HIGH LONGTERM - 175/210/250/333+
Kopran
🔐 locked in 10% UC
181.90
🔐 locked in 10% UC
181.90
🔆Stock market gave excellent opportunity in March'20 & April'20
🔆ONLY FEW TOOK IT AS OPPORTUNITY & MAX PANIC.
🔆Stock market gave an excellent opportunity yet again in April 2021 & possible in May 2021 also.
🔆LOOK FUTURE GROWTH#THINK AS AN INVESTOR # STOCK SPECIFIC OPPORTUNITY#
🔆Covid disappeared for few months in 2020, it will disappear for much BIGGER duration very soon.
⚜TRADERS EARN GOOD MONEY 💰
🎯INVESTORS CREATE WEALTH 🎯
Join our Free Educational Telegram Channel
t.me/wealthcreature
🔆ONLY FEW TOOK IT AS OPPORTUNITY & MAX PANIC.
🔆Stock market gave an excellent opportunity yet again in April 2021 & possible in May 2021 also.
🔆LOOK FUTURE GROWTH#THINK AS AN INVESTOR # STOCK SPECIFIC OPPORTUNITY#
🔆Covid disappeared for few months in 2020, it will disappear for much BIGGER duration very soon.
⚜TRADERS EARN GOOD MONEY 💰
🎯INVESTORS CREATE WEALTH 🎯
Join our Free Educational Telegram Channel
t.me/wealthcreature
Telegram
Wealthcreatures.com
Visit us at www.wealthcreatures.com
Driven by Fundamentals and Leveraging Technicals.
All post are Only For Study & Educational Purpose.consult you Financial Advisor Before Investing or taking any position.
DISCLAIMER:We r Not SEBI REGISTERED ANALYST.
Driven by Fundamentals and Leveraging Technicals.
All post are Only For Study & Educational Purpose.consult you Financial Advisor Before Investing or taking any position.
DISCLAIMER:We r Not SEBI REGISTERED ANALYST.
MASTEK
Q4FY21 SUPERB NUMBERS
STRONG CASH FLOW
REVENUE # 487cr vs 354cr
PBT # 97cr vs 49cr
IN Q3 PBT # 94cr
PAT # 76cr vs 39cr
Q3 PAT # 70cr
Q4 EPS # 24.3
FULL YEAR FY21 EPS # 84.92
Final DIVIDEND # RS.9 ( whole year dividend 5.5 + 9 = 14.5)
9% Dividend yield from our 1st Reco Levels
Q4FY21 SUPERB NUMBERS
STRONG CASH FLOW
REVENUE # 487cr vs 354cr
PBT # 97cr vs 49cr
IN Q3 PBT # 94cr
PAT # 76cr vs 39cr
Q3 PAT # 70cr
Q4 EPS # 24.3
FULL YEAR FY21 EPS # 84.92
Final DIVIDEND # RS.9 ( whole year dividend 5.5 + 9 = 14.5)
9% Dividend yield from our 1st Reco Levels
FEW OF OUR RECO PICK MAKING NEW 52WK HIGH
MASTEK # 1599 🎯
( 1st Reco @ 169)
KOPRAN # 183.45 🎯
(1st Reco @ 36)
BAJAJ FINSERV # 10869 🎯
(1st Reco@ 4705)
MOREPEN LABS # 59.40 🎯
(Reco @ 37)
KPIT TECH # 209 🎯
(1st Reco@ 143)
CAMS # 2429
(1st Reco @1405)
CDSL # 825
(1st Reco@500)
MASTEK # 1599 🎯
( 1st Reco @ 169)
KOPRAN # 183.45 🎯
(1st Reco @ 36)
BAJAJ FINSERV # 10869 🎯
(1st Reco@ 4705)
MOREPEN LABS # 59.40 🎯
(Reco @ 37)
KPIT TECH # 209 🎯
(1st Reco@ 143)
CAMS # 2429
(1st Reco @1405)
CDSL # 825
(1st Reco@500)
Wealthcreatures.com
Next 2 to 3 Days Movement will decide Trend in Nifty Nifty Important Support @ 14140/14050 Below 14040 close # 13850/13600/13440 Nifty Resistance # 14585/14660 Trend change for Nifty if it closes Above 14600 Above 14675 # 14800/14960/15050 STOCK SPECIFIC…
NIFTY
JUST CHECK VIEW
ALL MOVING AS PER VIEW
NIFTY # Today HIGH # 15044
Above Trend change all levels Hit # 14800/14900/15050 ( High 15044)
JUST CHECK VIEW
ALL MOVING AS PER VIEW
NIFTY # Today HIGH # 15044
Above Trend change all levels Hit # 14800/14900/15050 ( High 15044)
MORE PICKS MAKING NEW 52WK HIGH
CONFIDENCE PETRO # 55.65
( Reco @ 37.15)
CYIENT # 774
(1st Reco @ 255)
GOOD LUCK STEEL # 98
( Reco @ 50)
GNFC # 367
(1st Reco @ 100)
FILATEX INDIA # 82.45
(Reco @ 74)
GALAXY SURFACTANTS # 2975
1st Reco @ 2100)
HIKAL # 277
( 1st Reco @ 135)
GRAPHITE # 748
( 1st Reco @ 243)
MAITHAN ALLOY # 806
(Reco @ 583)
LAURUS LAB # 482
(Reco @ 300 Before split & @ 250 recently)
LINCOLN PHARMA # 286
(Reco @ 240)
TINPLATE # 203
( Reco @ 167)
SURYA ROSHNI # 431
(Reco @ 240)
TATA STEEL BSL # 69.95
(1st Reco @ 42)
HOW TO SEE PREVIOUS ALL RECOMMENDED PICK
(Click on THREE Dots on right side ON ur Telegram -- Go to search -- search for stock in That and You can see all details about that stock)
CONFIDENCE PETRO # 55.65
( Reco @ 37.15)
CYIENT # 774
(1st Reco @ 255)
GOOD LUCK STEEL # 98
( Reco @ 50)
GNFC # 367
(1st Reco @ 100)
FILATEX INDIA # 82.45
(Reco @ 74)
GALAXY SURFACTANTS # 2975
1st Reco @ 2100)
HIKAL # 277
( 1st Reco @ 135)
GRAPHITE # 748
( 1st Reco @ 243)
MAITHAN ALLOY # 806
(Reco @ 583)
LAURUS LAB # 482
(Reco @ 300 Before split & @ 250 recently)
LINCOLN PHARMA # 286
(Reco @ 240)
TINPLATE # 203
( Reco @ 167)
SURYA ROSHNI # 431
(Reco @ 240)
TATA STEEL BSL # 69.95
(1st Reco @ 42)
HOW TO SEE PREVIOUS ALL RECOMMENDED PICK
(Click on THREE Dots on right side ON ur Telegram -- Go to search -- search for stock in That and You can see all details about that stock)
👍1
Wealthcreatures.com
#TatasteelBSL 51 SL 37.50 MCB T - minimum 90/100
Presenting you none other than Our Favorite Pick TataSteelBSL
Dot 70.00
Simple Waves
💚💚💚
Those who missed At 42 Told to add near 51 Levels..
Dot 70.00
Simple Waves
💚💚💚
Those who missed At 42 Told to add near 51 Levels..
Wealthcreatures.com
https://wealthcreatures.com/2020/03/25/visaka-inds-can-past-glory-of-stock-return-back-in-next-5-year-again-only-time-would-tell/ 💚VISAKA INDS 💚 🔆 FY21 Q4 UPDATE # SUPERB NUMBERS 🔆Net profit Up 350% To Rs.30.80 cr (YoY) 🔆Revenue Up 55% To Rs.354 cr (YOY)…
VISAKA INDS
6X RETURNS
NEW 52WK HIGH
604
94 To 604 Done Till Now in just 1 year.
Long way To Go
6X RETURNS
NEW 52WK HIGH
604
94 To 604 Done Till Now in just 1 year.
Long way To Go
Wealthcreatures.com
LAURUS 270.05 START ADDING ON DIPS FOR INVESTMENT IF YOUR VIEW IS 12 TO 18 MONTHS ADD MORE @ 250/240
LAURUS LAB
SUPERB NUMBERS
CONSISTENT PERFORMER
EXPECTING SAME WAY TO PERFORM GOING FORWARD NXT 6 TO 12 QTRS
Revenue from Operations came at Rs. 1411.9 Cr (9.6% QoQ, 68.3% YoY) vs expectation of Rs. 1358.4 Cr,
QoQ Rs. 1288.4 Cr, YoY Rs. 839.1 Cr
EBIDTA came at Rs. 450.3 Cr (5.6% QoQ, 134.8% YoY) vs expectation of Rs. 456 Cr, QoQ Rs. 426.3 Cr, YoY Rs. 191.8 Cr
EBITDA Margin came at 31.9% vs expectation of 33.6%
QoQ 33.1%, YoY 22.9%
PAT came at Rs. 296.9 Cr vs expectation of Rs. 296.2 Cr
QoQ Rs. 272.9 Cr, YoY Rs. 110.2 Cr
SUPERB NUMBERS
CONSISTENT PERFORMER
EXPECTING SAME WAY TO PERFORM GOING FORWARD NXT 6 TO 12 QTRS
Revenue from Operations came at Rs. 1411.9 Cr (9.6% QoQ, 68.3% YoY) vs expectation of Rs. 1358.4 Cr,
QoQ Rs. 1288.4 Cr, YoY Rs. 839.1 Cr
EBIDTA came at Rs. 450.3 Cr (5.6% QoQ, 134.8% YoY) vs expectation of Rs. 456 Cr, QoQ Rs. 426.3 Cr, YoY Rs. 191.8 Cr
EBITDA Margin came at 31.9% vs expectation of 33.6%
QoQ 33.1%, YoY 22.9%
PAT came at Rs. 296.9 Cr vs expectation of Rs. 296.2 Cr
QoQ Rs. 272.9 Cr, YoY Rs. 110.2 Cr
Rain Inds Q4 FY21 Update
GOOD NUMBERS
REVENUE # 3000crs v/s 2897crs(YoY) & 2640crs (QoQ)
EBIDTA margin at 21.1% v/s 19.3% (YoY) & 18.2% (QoQ)
PAT # 215crs v/s 205crs (YoY) & 115crs (QoQ)
Net Debt @ $900mn. $19mn spent out of the $47mn capex.
GOOD NUMBERS
REVENUE # 3000crs v/s 2897crs(YoY) & 2640crs (QoQ)
EBIDTA margin at 21.1% v/s 19.3% (YoY) & 18.2% (QoQ)
PAT # 215crs v/s 205crs (YoY) & 115crs (QoQ)
Net Debt @ $900mn. $19mn spent out of the $47mn capex.
Do you guys want to know Key Takeaways from Mastek Management Concall and why will it be multibagger?
Anonymous Poll
97%
Yes , I want to Read and Learn
3%
No , I don't want to Read and Learn
https://wealthcreatures.com/2020/03/30/mastek/
❇️ MASTEK ❇️
Hits NEW ALL TIME HIGH
1⃣6⃣8⃣0⃣ 🎯🎯
1st Reco @ 169 on 30th MARCH'20 & Multiple Times @ 700/1000/1200 also
🔆 In just 13 months 169 TO 1680 ♨️ ( 1000% Almost)
🔆 10X RETURNS IN JUST 13 Months
🔆 LONG WAY TO GO
CONVICTION#FUNDAMENTALS#
CONFIDENCE TO BUY WHEN BLOODBATH# WEALTHCREATURE
Stay Tunned Many Such Ideas 💡 coming
❇️ MASTEK ❇️
Hits NEW ALL TIME HIGH
1⃣6⃣8⃣0⃣ 🎯🎯
1st Reco @ 169 on 30th MARCH'20 & Multiple Times @ 700/1000/1200 also
🔆 In just 13 months 169 TO 1680 ♨️ ( 1000% Almost)
🔆 10X RETURNS IN JUST 13 Months
🔆 LONG WAY TO GO
CONVICTION#FUNDAMENTALS#
CONFIDENCE TO BUY WHEN BLOODBATH# WEALTHCREATURE
Stay Tunned Many Such Ideas 💡 coming
WealthCreatures
MASTEK
CMP – 169MARKET CAP – 430 crBOOK VALUE – 28852wk HIGH/LOW – 508/1665 Year HIGH/LOW – 644/105FACE VALUE – 5DIVIDEND YIELD – 4.75%Trading at very Attractive …
Wealthcreatures.com
Two of our Reco Stocks Getting Ready for 10x in next few months. We expecting # 20x/25× within 1.5 to 3 years
Had given indication before 7 days
1st # Deepak Nitrite # Already 11x
2nd # MASTEK # 10x
1st # Deepak Nitrite # Already 11x
2nd # MASTEK # 10x
MASTEK # CONCALL & INVESTOR PRESENTATION
"In 5 years, it took the Mastek to get first 10 million+ deal and then in next 1 year the company got two of those."
Here are the concall highlights 😃
Overview
- 42% YoY growth rate because of the order book growth which was 70 to 80% more than the revenue
- Synergy of evosys and mastek will lead to more growth.
- Completely focused on digital cloud space which is growing the fastest.
- Added enough people in leadership and skillset.
- Company has clarity about the strategy and future acquisition.
- Lot of work rhe company is in is related with government and is about security.
- Signed with 25 million + pound deal with an existing customer.
- Signed a new logo for a long term engagement which became the fastest 10 million pound engagement in 6 months.
- Company is engaged with NHS in UK.
- Order book grew almost by 90%.
- Public sector grew by 35%.
- Company has bids which are in the pipeline which are more than 35 million pounds each.
- Company has partnered in the digital space with a Japanese company (HQ in UK)
- Cloud capability and cloud space is the focus.
- Company has entered into 3 large deals in UK Healthcare.
- Company has acquired first customer in local government space.
- The company wants to understand the market and develop itself in it coz the potential is huge.
- Record number of new contracts came in US business
- Growth in the coming times: most of them are 8n the retail space which have a significant IT wallet.
- Cross industry cooperation and competition is becoming real
- There is a higher demand of touch less retail space
North America business :
- Focus to increase business in North America.
- Continued to inves in America by doubling the employees
- No. Of customers are much more sizeable in North America
- Growth is targeted towards Healthcare & lifesciences manufacturing and retail.
- Revenue is still about 20% from US. Aim is to have a similar growth which the company has thus quarter.
- Focus is towards doubling if order book is US.
"In 5 years, it took the Mastek to get first 10 million+ deal and then in next 1 year the company got two of those."
Here are the concall highlights 😃
Overview
- 42% YoY growth rate because of the order book growth which was 70 to 80% more than the revenue
- Synergy of evosys and mastek will lead to more growth.
- Completely focused on digital cloud space which is growing the fastest.
- Added enough people in leadership and skillset.
- Company has clarity about the strategy and future acquisition.
- Lot of work rhe company is in is related with government and is about security.
- Signed with 25 million + pound deal with an existing customer.
- Signed a new logo for a long term engagement which became the fastest 10 million pound engagement in 6 months.
- Company is engaged with NHS in UK.
- Order book grew almost by 90%.
- Public sector grew by 35%.
- Company has bids which are in the pipeline which are more than 35 million pounds each.
- Company has partnered in the digital space with a Japanese company (HQ in UK)
- Cloud capability and cloud space is the focus.
- Company has entered into 3 large deals in UK Healthcare.
- Company has acquired first customer in local government space.
- The company wants to understand the market and develop itself in it coz the potential is huge.
- Record number of new contracts came in US business
- Growth in the coming times: most of them are 8n the retail space which have a significant IT wallet.
- Cross industry cooperation and competition is becoming real
- There is a higher demand of touch less retail space
North America business :
- Focus to increase business in North America.
- Continued to inves in America by doubling the employees
- No. Of customers are much more sizeable in North America
- Growth is targeted towards Healthcare & lifesciences manufacturing and retail.
- Revenue is still about 20% from US. Aim is to have a similar growth which the company has thus quarter.
- Focus is towards doubling if order book is US.